Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2023-02-09 Declaration of Voting R…
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023.' and explicitly references Article 223-16 of the French AMF general regulation. It provides a table detailing the total number of shares and voting rights as of the end of January 2023, with prior month comparisons. This content directly relates to the official disclosure of voting rights and share capital structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it is a mandatory monthly disclosure regarding voting rights.
2023-02-09 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2022
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 31 décembre 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of December 31, 2022). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF), which mandates monthly disclosure of total voting rights and share capital. This type of periodic disclosure, focusing on share capital structure and voting rights, aligns best with filings related to capital changes or general regulatory reporting. Since it is a specific, recurring regulatory disclosure about the number of shares and voting rights, it is most closely related to Share Issue/Capital Change (SHA) or a general Regulatory Filing (RNS). Given the specific nature of tracking share capital and voting rights monthly, it is a form of capital structure update, but it is not a declaration of a specific transaction (like a buyback or new issue). However, the closest fit among the provided options for a mandatory, periodic report detailing the composition of the share capital and voting rights is often categorized under capital structure changes or general regulatory reporting. Since it is a formal, mandatory monthly report on the capital structure, it is best classified as a Regulatory Filing (RNS) as it is a specific regulatory disclosure that doesn't fit the other categories perfectly, although it touches upon capital structure. If a specific 'Share Capital Disclosure' code existed, it would be preferred. Given the options, RNS is the most appropriate fallback for a specific, recurring regulatory disclosure not covered elsewhere. The document length is short (2502 chars), but it is the report itself, not an announcement of a report.
2023-01-09 French
Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022
Share Issue/Capital Change Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2022." It provides a table detailing the evolution of the total number of shares and voting rights over a year, referencing the French AMF regulation (Article 223-16). This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement, often falling under general regulatory announcements or specific capital structure disclosures. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory update concerning share capital structure, it is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA) if it were announcing a change, but here it is a monthly status report. Given the nature of mandatory monthly disclosure of voting rights, RNS is the most appropriate general regulatory category, as it is not a standard 10-K, ER, or IR. It is a formal regulatory filing.
2023-01-09 English
Franchissements de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclaration de franchissements de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing specifically reports changes in significant share ownership, where an entity crosses ownership thresholds (like 5%). This directly corresponds to the definition of Major Shareholding Notification (MRQ). The text details that BVF Partners LP crossed the 5% threshold of voting rights and capital on specific dates in December 2022. The document is a regulatory disclosure concerning share ownership changes, not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but fits the specific category MRQ.
2023-01-06 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It details a shareholder, BVF Partners LP, crossing below the 10% threshold of capital and voting rights in ERYTECH PHARMA on December 23, 2022. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and specific to this regulatory event.
2023-01-02 French
Franchissement de seuil
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuil (article L. 233-7 du code de commerce)" and details that BVF Partners LP crossed below the 15% ownership threshold of ERYTECH PHARMA's capital on December 8, 2022. This type of filing, which reports changes in significant share ownership levels crossing regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains specific regulatory reporting details, confirming it is a direct filing rather than an announcement of a report.
2022-12-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.